These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 36821999)

  • 1. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
    Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
    Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma.
    Yang RH; Qin J; Cao JL; Zhang MZ; Li YY; Wang MQ; Fang D; Xie SQ
    Biochem Pharmacol; 2023 Feb; 208():115378. PubMed ID: 36513141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
    Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
    Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma.
    Shi HX; Liang C; Yao CY; Gao ZX; Qin J; Cao JL; Zhang MZ; Li YY; Wang MQ; Sun H; Xie SQ; Fang D
    Cell Commun Signal; 2022 Nov; 20(1):175. PubMed ID: 36348350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
    Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
    Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
    Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
    Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
    Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
    Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
    Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
    Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
    Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
    J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.
    Zhou Z; Li X; Yang G; Wang J; Li B; Huang Y; Yan J; Tao K
    Theranostics; 2023; 13(10):3371-3386. PubMed ID: 37351175
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
    Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
    Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity.
    Park SH; Lee J; Yun HJ; Kim SH; Lee JH
    Ann Lab Med; 2024 Sep; 44(5):426-436. PubMed ID: 38529546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
    Wei H; Mao Y; Zhang H; Wu F; Zhang Y
    Immunol Invest; 2023 Apr; 52(3):343-363. PubMed ID: 36762677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
    Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
    J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.